Detection of bcr-abl1 mrna in platelets and cfrna from chronic myeloid leukaemia patients
Başlık çevirisi mevcut değil.
- Tez No: 797800
- Danışmanlar: DR. JAMSHID SOROURI KHORASHAD, DR. KATHY DOMINY
- Tez Türü: Yüksek Lisans
- Konular: Genetik, Moleküler Tıp, Genetics, Molecular Medicine
- Anahtar Kelimeler: Belirtilmemiş.
- Yıl: 2019
- Dil: İngilizce
- Üniversite: Imperial College London
- Enstitü: Yurtdışı Enstitü
- Ana Bilim Dalı: Belirtilmemiş.
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: 59
Özet
Özet yok.
Özet (Çeviri)
Chronic Myeloid Leukaemia (CML) is a bone marrow cancer of white blood cells originating from myeloid stem cell lineage, causing uncontrolled proliferation and accumulation of granulocytes. It is characterized by formation of BCR-ABL1 fusion oncogene, also referred to as Philadelphia chromosome, through reciprocal translocation between chromosomes 9 and 22, which results in constitutively active BCR-ABL1 tyrosine kinase and consequently abnormal alterations in the activation of the downstream effectors/signalling pathways. Regular monitoring of residual BCRABL1 transcript levels in CML patients provides crucial information about molecular response of patients to an applied treatment, as well as their prognosis and predicted clinical outcome. Patients achieving more than 4 log reductions in their BCR-ABL1 transcript numbers (equal or less than 0.01 % BCR-ABL1 of the original amount) are considered to be expressing a“deep molecular response”which is an essential indicator for the patient to enter treatment-free disease remission phase. Existing quantitative (real-time) polymerase chain reaction (qPCR) detection is not sensitive enough to differentiate patients who lose their deep molecular response upon stopping therapy from those who still acquire it. This paper aimed to investigate an alternative and novel detection method of BCR-ABL1 transcripts in platelets and blood plasma (as in cell-free RNA form) rather than in white blood cells, with qPCR as a potential prognostic measure to further investigate minimal residual disease especially in patients with undetectable transcript levels in their white blood cells (WBCs). In this study, our hypothesis was that BCR-ABL1 transcripts could be detected in cfRNA and especially in platelets with higher sensitivity compared to WBCs. Results showed that, detection of BCR-ABL1 mRNA in white blood cells was still much more sensitive compared to attempting to determine the levels in platelets and cfRNA. Platelets and cfRNA weren't found to be better sources than white blood cells for monitoring of transcript levels, at least not in CML
Benzer Tezler
- Kronik myeloid lösemi hastalarında hipofiz tümörü transforme edici gen (PTTG) ekspresyonunun değerlendirilmesi
Evaluation of pituitary tumor transforming gene (pttg) expression in chronic myeloid leukemia patients
MERVE GENÇER ÇELİKEL
Yüksek Lisans
Türkçe
2019
GenetikNecmettin Erbakan ÜniversitesiTıbbi Genetik Ana Bilim Dalı
DOÇ. DR. AYŞE GÜL ZAMANİ
- CRISPR/cas9 sistemi ile bcr/abl gen füzyonunun in vitro kalitatif analizi
In vitro qualitative analysis of BCR/ABL gene fusion with crispr/CAS9 system
FEHİME DENİZ KANAT
Yüksek Lisans
Türkçe
2020
GenetikBaşkent ÜniversitesiTıbbi Genetik Ana Bilim Dalı
DOÇ. DR. YUNUS KASIM TERZİ
- Akut lenfoblastik lösemi (ALL) ve akut miyeloid lösemi (AML)'de prognozu etkileyen KMT2A anomalilerinin sıklığı
Frequency of KMT2A abnormalities affecting prognosis in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
RAPERİN ESER
Yüksek Lisans
Türkçe
2023
GenetikDicle ÜniversitesiMoleküler Biyoloji ve Genetik Ana Bilim Dalı
PROF. DR. KEMAL GÜVEN
- CRISPR/CAS9 teknolojisi kullanılarak A549, NCI-H1155 akciğer kanser hücre hatlarında P53 geni ve K562 kronik myeloid lösemili hücre hattında BCR/ABL1 ve SK1 genlerinde düzenleme yapılması
Editing of BCR/ABL1 and SK1 genes in K562 chronic myeloidleukemia cell line and in the P53 gene in A549, NCI-H1155 lungcancer cell lines using CRISPR/CAS9 technology
TARIK GÖKBULUT
Doktora
Türkçe
2019
BiyolojiErciyes ÜniversitesiBiyoloji Ana Bilim Dalı
PROF. DR. MİKAİL AKBULUT
PROF. DR. YUSUF BARAN
- Kronik myelositer lösemide BCR-ABL füzyon transkriptlerinin RT-PCR tekniği kullanılarak nicel olarak belirlenmesi
The Quantitative detection of BCR-ABL fusion transcripts by using RT-PCR technique in chronic myeloid leukemia
FATİH BARIŞ
Yüksek Lisans
Türkçe
2002
GastroenterolojiAnkara Üniversitesiİç Hastalıkları Ana Bilim Dalı
PROF.DR. MERAL BEKSAÇ